Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers

Novartis

Status: Completed

Conditions: Sickle Cell Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT05833022

CSEG101AUS16

Details and patient eligibility

About

This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.

Enrollment: 297 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Any patient with diagnosis of SCD based on high-performance liquid chromatography (HPLC) or hemoglobin electrophoresis at treating institution
• Treatment order for crizanlizumab; Index date was defined as the date for the first crizanlizumab treatment
• At least 12 months of available electronic medical record (EMR) data pre-index date (baseline)
• Patients must have received at least one dose of crizanlizumab
• For inclusion in pre/post analysis of effectiveness, patients must have received at least 6 doses of medication. The rates could be annualized if total post-index time was <12 months.

Exclusion criteria

None specified